Pentoxifylline can decrease the AST (Aspartate aminotransfrase) and ALT (Alanin aminotransfrase) levels and its anti-TNF-α effect also improves symptoms of liver tissue in patients with NALFD (Non-alcoholic steatohepatitis)/NASH Non-alcoholic fatty liver disease (43). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.